Latest News & Features
Big Pharma
Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court. 25 November 2021
Americas
Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha. 25 November 2021
Americas
Pfizer is currently investigating a soon-to-be former employee who it believes has transferred more than 12,000 files, many of which contain confidential and trade secret information, to her personal devices and has repeatedly attempted to cover her tracks. 25 November 2021
Americas
BioMarin Pharmaceuticals has accused a former engineer who went to work for competitor Sangamo Therapeutics of stealing more than 1,800 files containing confidential information and trade secrets. 23 November 2021
Generics
Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar. 23 November 2021
Biotechnology
Medical and human rights groups have called on US President Joe Biden to step up his personal engagement and help put in place a temporary waiver of IP rights for COVID-19 vaccines. 23 November 2021
Big Pharma
Pfizer is the latest pharmaceutical company to sign a licensing agreement with the Medicines Patent Pool to help increase access to its COVID-19 oral antiviral treatment candidate PAXLOVID for low and middle-income countries. 18 November 2021
Americas
The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital. 18 November 2021
Americas
EpiPen buyers have secured final approval of a $345 million settlement with Pfizer in a consumer antitrust suit. 18 November 2021
article
In this session Takanori Abe will explore the reasons why reverse payment cases are so scant in Japan. With their low invalidation rate of substance patents, and the stable supply obligation after the launch of generic drugs, the system in Japan makes reverse payments very difficult. On the other hand, the reasons why actual reverse payments cases have not arisen in Japan cannot be solely explained by the systems in place. The attitude of Japanese companies’ towards regulatory authorities may be a significant factor. 18 November 2021